A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and INFANRIX hexa in Pneumococcal Vaccines, sponsored by Pfizer. Completed at 14 sites in Poland. Open to participants aged 56 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-26.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Paracetamol
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Ibuprofen
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Paracetamol
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa · Drug: Ibuprofen
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: INFANRIX hexa
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series
Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
Time frame: 1 month after the infant series
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose
Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively.
Time frame: 1 month after the toddler dose
Percentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series
Percentage of participants achieving serotype-specific pneumococcal OPA titer \>= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13.
Time frame: 1 month after the infant series
Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series
Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series
Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series
Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series
Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
Time frame: 1 month after the infant series
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series
Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
Time frame: 1 month after the infant series
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose
Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose
Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose
Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
Time frame: 1 month after the toddler dose
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose
Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
Time frame: 1 month after the toddler dose
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose
Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
Time frame: 1 month after the toddler dose
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.6 EU/mL, FHA \>=16.1 EU/mL, PRN \>=24.0 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
Time frame: 1 month after the infant series
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.8 EU/mL, FHA \>=46.5 EU/mL, PRN \>=43.5 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
Time frame: 1 month after the toddler dose
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1
Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree Celsius (degree C), greater than (\>) 39 but \<=40 degree C and \>40 degree C.
Time frame: Within 4 days after infant series Dose 1
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.
Time frame: Within 4 days after infant series Dose 2
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C. Report of fever \>40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error.
Time frame: Within 4 days after infant series Dose 3
Percentage of Participants Reporting Fever Within 4 Days: Toddler Dose
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.
Time frame: Within 4 days after toddler dose
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
Time frame: Baseline up to 1 Month (28 to 42 days) after infant series
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment).
Time frame: 1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
Time frame: Toddler dose up to 1 Month (28 to 42 days) after toddler dose
| Milestone | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Started | 173 | 176 | 172 | 177 | 210 |
| Vaccinated dose 1 | 173 | 176 | 172 | 177 | 210 |
| Vaccinated dose 2 | 171 | 174 | 172 | 177 | 210 |
| Vaccinated dose 3 | 170 | 174 | 172 | 176 | 210 |
| Completed | 169 | 174 | 172 | 175 | 210 |
| Not completed | 4 | 2 | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent | 4 | 1 | 0 | 0 | 0 |
| Milestone | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Started | 169 | 174 | 172 | 175 | 210 |
| Completed | 169 | 173 | 170 | 175 | 209 |
| Not completed | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent | 0 | 1 | 1 | 0 | 1 |
| Milestone | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Started | 169 | 173 | 170 | 175 | 209 |
| Completed | 169 | 172 | 170 | 173 | 208 |
| Not completed | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by parent | 0 | 1 | 0 | 1 | 1 |
Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
| microgram per milliliter (mcg/mL) | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| 4 (n = 137, 155, 148, 146, 210) | 1.64 (1.44 to 1.87) | 1.99 (1.76 to 2.25) | 1.48 (1.31 to 1.68) | 2.07 (1.82 to 2.34) | 2.02 (1.82 to 2.25) |
| 6B (n = 136, 155, 148, 146, 210) | 0.68 (0.55 to 0.83) | 0.91 (0.76 to 1.10) | 0.56 (0.46 to 0.68) | 0.90 (0.74 to 1.09) | 0.81 (0.69 to 0.96) |
| 9V (n = 138, 155, 148, 147, 210) | 1.13 (1.01 to 1.27) | 1.45 (1.30 to 1.61) | 1.17 (1.05 to 1.30) | 1.40 (1.26 to 1.56) | 1.31 (1.19 to 1.43) |
| 14 (n = 138, 155, 148, 147, 210) | 4.45 (3.76 to 5.26) | 4.73 (4.04 to 5.54) | 4.75 (4.04 to 5.58) | 5.26 (4.48 to 6.19) | 5.38 (4.70 to 6.16) |
| 18C (n = 138, 155, 148, 147, 210) | 1.47 (1.29 to 1.66) | 1.73 (1.54 to 1.95) | 1.25 (1.11 to 1.42) | 1.75 (1.55 to 1.97) | 1.54 (1.39 to 1.70) |
| 19F (n = 138, 155, 148, 147, 210) | 1.78 (1.57 to 2.02) | 2.30 (2.04 to 2.59) | 1.59 (1.41 to 1.80) | 2.04 (1.81 to 2.31) | 1.99 (1.80 to 2.20) |
| 23F (n= 137, 155, 148, 146, 210) | 0.85 (0.72 to 1.00) | 1.19 (1.02 to 1.40) | 0.73 (0.62 to 0.86) | 1.07 (0.91 to 1.26) | 1.04 (0.91 to 1.19) |
| 1 (n = 138, 155, 148, 147, 210) | 1.12 (0.98 to 1.27) | 1.50 (1.33 to 1.69) | 1.02 (0.90 to 1.16) | 1.29 (1.14 to 1.47) | 1.25 (1.12 to 1.38) |
| 3 (n = 138, 155, 148, 147, 210) | 0.71 (0.63 to 0.79) | 0.83 (0.75 to 0.93) | 0.57 (0.51 to 0.64) | 0.84 (0.75 to 0.94) | 0.88 (0.79 to 0.96) |
| 5 (n = 137, 155, 148, 146, 210) | 0.79 (0.69 to 0.91) | 0.98 (0.86 to 1.11) | 0.63 (0.55 to 0.72) | 0.90 (0.78 to 1.02) | 0.81 (0.73 to 0.91) |
| 6A (n = 138, 155, 148, 146, 210) | 0.97 (0.84 to 1.13) | 1.25 (1.09 to 1.44) | 0.85 (0.74 to 0.98) | 1.22 (1.06 to 1.41) | 1.10 (0.97 to 1.24) |
| 7F (n = 138, 155, 148, 146, 210) | 1.94 (1.74 to 2.16) | 2.22 (2.01 to 2.46) | 1.83 (1.65 to 2.03) | 2.28 (2.06 to 2.53) | 2.15 (1.97 to 2.34) |
| 19A (n = 137, 155, 148, 146, 210) | 2.70 (2.38 to 3.07) | 3.39 (3.01 to 3.82) | 2.53 (2.24 to 2.86) | 3.14 (2.77 to 3.55) | 3.02 (2.72 to 3.34) |
Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| 4 (n = 137, 155, 148, 146, 210) | 96.4 (91.69 to 98.80) | 97.4 (93.52 to 99.29) | 96.6 (92.29 to 98.89) | 97.3 (93.13 to 99.25) | 98.1 (95.20 to 99.48) |
| 6B (n = 136, 155, 148, 146, 210) | 72.8 (64.50 to 80.07) | 80.0 (72.83 to 85.99) | 61.5 (53.14 to 69.36) | 79.5 (71.98 to 85.69) | 77.6 (71.37 to 83.07) |
| 9V (n = 138, 155, 148, 147, 210) | 94.2 (88.90 to 97.46) | 99.4 (96.46 to 99.98) | 95.9 (91.39 to 98.50) | 95.9 (91.33 to 98.49) | 96.2 (92.63 to 98.34) |
| 14 (n = 138, 155, 148, 147, 210) | 100.0 (97.36 to 100.00) | 98.7 (95.42 to 99.84) | 99.3 (96.29 to 99.98) | 98.6 (95.17 to 99.83) | 99.5 (97.38 to 99.99) |
| 18C (n = 138, 155, 148, 147, 210) | 96.4 (91.75 to 98.81) | 97.4 (93.52 to 99.29) | 95.3 (90.50 to 98.08) | 95.9 (91.33 to 98.49) | 96.7 (93.25 to 98.65) |
| 19F (n = 138, 155, 148, 147, 210) | 97.1 (92.74 to 99.20) | 99.4 (96.46 to 99.98) | 95.3 (90.50 to 98.08) | 96.6 (92.24 to 98.89) | 97.6 (94.53 to 99.22) |
| 23F (n = 137, 155, 148, 146, 210) | 86.1 (79.19 to 91.44) | 90.3 (84.54 to 94.48) | 74.3 (66.50 to 81.15) | 88.4 (82.01 to 93.07) | 88.1 (82.93 to 92.15) |
| 1 (n = 138, 155, 148, 147, 210) | 94.2 (88.90 to 97.46) | 97.4 (93.52 to 99.29) | 90.5 (84.64 to 94.73) | 94.6 (89.56 to 97.62) | 94.3 (90.23 to 97.01) |
| 3 (n = 138, 155, 148, 147, 210) | 83.3 (76.05 to 89.13) | 89.7 (83.78 to 93.98) | 81.1 (73.83 to 87.05) | 88.4 (82.13 to 93.12) | 91.0 (86.23 to 94.46) |
| 5 (n = 137, 155, 148, 146, 210) | 84.7 (77.53 to 90.25) | 91.0 (85.31 to 94.97) | 76.4 (68.68 to 82.94) | 89.7 (83.62 to 94.13) | 84.3 (78.65 to 88.93) |
| 6A (n = 138, 155, 148, 146, 210) | 86.2 (79.34 to 91.50) | 92.3 (86.87 to 95.94) | 83.1 (76.08 to 88.76) | 91.8 (86.08 to 95.68) | 91.9 (87.36 to 95.21) |
| 7F (n = 138, 155, 148, 146, 210) | 100.0 (97.36 to 100.00) | 99.4 (96.46 to 99.98) | 97.3 (93.22 to 99.26) | 100.0 (97.51 to 100.00) | 99.5 (97.38 to 99.99) |
| 19A (n = 137, 155, 148, 146, 210) | 98.5 (94.83 to 99.82) | 99.4 (96.46 to 99.98) | 98.0 (94.19 to 99.58) | 99.3 (96.24 to 99.98) | 100.0 (98.26 to 100.00) |
Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively.
| mcg/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| 4 (n = 130, 144, 143, 139, 206) | 3.07 (2.66 to 3.54) | 3.43 (3.00 to 3.93) | 2.97 (2.60 to 3.41) | 3.43 (2.99 to 3.94) | 3.10 (2.77 to 3.48) |
| 6B (n = 130, 144, 143, 139, 206) | 6.70 (5.76 to 7.78) | 8.01 (6.94 to 9.24) | 6.38 (5.53 to 7.36) | 7.30 (6.31 to 8.44) | 7.08 (6.28 to 7.98) |
| 9V (n = 130, 144, 143, 139, 206) | 2.15 (1.93 to 2.40) | 2.23 (2.01 to 2.47) | 2.17 (1.96 to 2.41) | 2.12 (1.91 to 2.35) | 2.16 (1.99 to 2.36) |
| 14 (n = 130, 144, 143, 139, 206) | 8.10 (7.04 to 9.31) | 8.40 (7.36 to 9.59) | 7.95 (6.96 to 9.08) | 9.12 (7.96 to 10.43) | 9.10 (8.15 to 10.17) |
| 18C (n = 130, 144, 143, 139, 206) | 1.35 (1.20 to 1.53) | 1.68 (1.49 to 1.88) | 1.36 (1.21 to 1.53) | 1.63 (1.45 to 1.84) | 1.59 (1.44 to 1.75) |
| 19F (n = 130, 144, 143, 139, 206) | 8.41 (7.17 to 9.87) | 8.99 (7.72 to 10.46) | 7.53 (6.47 to 8.76) | 8.02 (6.88 to 9.36) | 7.95 (7.00 to 9.02) |
| 23F (n = 130, 144, 142, 139, 206) | 2.34 (2.01 to 2.73) | 2.96 (2.56 to 3.43) | 2.37 (2.05 to 2.75) | 2.86 (2.47 to 3.32) | 2.75 (2.43 to 3.10) |
| 1 (n = 130, 144, 143, 139, 206) | 2.80 (2.47 to 3.17) | 3.22 (2.85 to 3.62) | 2.66 (2.36 to 3.00) | 3.12 (2.76 to 3.52) | 3.04 (2.75 to 3.35) |
| 3 (n = 129, 144, 143, 138, 203) | 0.46 (0.40 to 0.52) | 0.54 (0.47 to 0.61) | 0.46 (0.40 to 0.52) | 0.49 (0.42 to 0.55) | 0.54 (0.48 to 0.60) |
| 5 (n = 130, 144, 143, 139, 206) | 2.33 (2.07 to 2.63) | 2.75 (2.46 to 3.07) | 2.40 (2.15 to 2.69) | 2.62 (2.33 to 2.93) | 2.84 (2.59 to 3.12) |
| 6A (n = 130, 144, 143, 139, 206) | 5.12 (4.48 to 5.86) | 5.73 (5.04 to 6.50) | 5.27 (4.64 to 5.99) | 5.36 (4.70 to 6.10) | 5.52 (4.97 to 6.14) |
| 7F (n = 130, 144, 142, 139, 206) | 3.79 (3.42 to 4.19) | 3.89 (3.54 to 4.28) | 3.56 (3.23 to 3.92) | 3.97 (3.60 to 4.38) | 3.98 (3.67 to 4.31) |
| 19A (n = 129, 144, 142, 139, 206) | 7.11 (6.22 to 8.12) | 7.99 (7.04 to 9.06) | 7.31 (6.43 to 8.30) | 7.35 (6.47 to 8.36) | 7.71 (6.94 to 8.57) |
Percentage of participants achieving serotype-specific pneumococcal OPA titer \>= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| 4 (n = 37, 46, 42, 41, 61) | 100.0 (90.5 to 100.0) | 100.0 (92.3 to 100.0) | 100.0 (91.6 to 100.0) | 100.0 (91.4 to 100.0) | 100.0 (94.1 to 100.0) |
| 6B (n = 36, 45, 43, 40, 62) | 94.4 (81.3 to 99.3) | 88.9 (75.9 to 96.3) | 88.4 (74.9 to 96.1) | 92.5 (79.6 to 98.4) | 96.8 (88.8 to 99.6) |
| 9V (n = 37, 48, 42, 41, 65) | 62.2 (44.8 to 77.5) | 66.7 (51.6 to 79.6) | 59.5 (43.3 to 74.4) | 80.5 (65.1 to 91.2) | 75.4 (63.1 to 85.2) |
| 14 (n = 38, 48, 41, 41, 64) | 89.5 (75.2 to 97.1) | 97.9 (88.9 to 99.9) | 100.0 (91.4 to 100.0) | 97.6 (87.1 to 99.9) | 96.9 (89.2 to 99.6) |
| 18C (n = 37, 47, 41, 41, 62) | 100.0 (90.5 to 100.0) | 95.7 (85.5 to 99.5) | 100.0 (91.4 to 100.0) | 97.6 (87.1 to 99.9) | 100.0 (94.2 to 100.0) |
| 19F (n = 37, 46, 41, 42, 63) | 97.3 (85.8 to 99.9) | 87.0 (73.7 to 95.1) | 90.2 (76.9 to 97.3) | 92.9 (80.5 to 98.5) | 95.2 (86.7 to 99.0) |
| 23F (n = 38, 45, 42, 42, 63) | 92.1 (78.6 to 98.3) | 97.8 (88.2 to 99.9) | 92.9 (80.5 to 98.5) | 90.5 (77.4 to 97.3) | 93.7 (84.5 to 98.2) |
| 1 (n = 42, 42, 43, 44, 74) | 47.6 (32.0 to 63.6) | 42.9 (27.7 to 59.0) | 30.2 (17.2 to 46.1) | 29.5 (16.8 to 45.2) | 45.9 (34.3 to 57.9) |
| 3 (n = 41, 41, 39, 39, 69) | 97.6 (87.1 to 99.9) | 97.6 (87.1 to 99.9) | 97.4 (86.5 to 99.9) | 94.9 (82.7 to 99.4) | 100.0 (94.8 to 100.0) |
| 5 (n = 42, 43, 44, 42, 73) | 92.9 (80.5 to 98.5) | 90.7 (77.9 to 97.4) | 86.4 (72.6 to 94.8) | 92.9 (80.5 to 98.5) | 86.3 (76.2 to 93.2) |
| 6A (n = 46, 42, 39, 39, 76) | 93.5 (82.1 to 98.6) | 100.0 (91.6 to 100.0) | 100.0 (91.0 to 100.0) | 100.0 (91.0 to 100.0) | 98.7 (92.9 to 100.0) |
| 7F (n = 46, 42, 40, 39, 76) | 100.0 (92.3 to 100.0) | 100.0 (91.6 to 100.0) | 100.0 (91.2 to 100.0) | 97.4 (86.5 to 99.9) | 100.0 (95.3 to 100.0) |
| 19A (n = 42, 44, 41, 42, 74) | 92.9 (80.5 to 98.5) | 100.0 (92.0 to 100.0) | 90.2 (76.9 to 97.3) | 88.1 (74.4 to 96.0) | 97.3 (90.6 to 99.7) |
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
| titer | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| 4 (n = 37, 46, 42, 41, 61) | 1269 (961.2 to 1674.2) | 1135 (885.2 to 1456.1) | 1240 (955.9 to 1609.3) | 1361 (1045.4 to 1771.0) | 1086 (874.9 to 1347.9) |
| 6B (n = 36, 45, 43, 40, 62) | 794 (450.4 to 1399.6) | 655 (394.6 to 1087.9) | 470 (279.9 to 789.7) | 663 (387.2 to 1135.1) | 748 (485.6 to 1152.0) |
| 9V (n = 37, 48, 42, 41, 65) | 120 (52.5 to 274.2) | 166 (80.5 to 343.3) | 93 (43.0 to 203.0) | 285 (129.8 to 623.8) | 241 (129.0 to 448.7) |
| 14 (n = 38, 48, 41, 41, 64) | 435 (277.2 to 683.5) | 622 (416.0 to 928.6) | 650 (420.7 to 1003.0) | 991 (642.1 to 1530.9) | 951 (671.6 to 1346.3) |
| 18C (n = 37, 47, 41, 41, 62) | 1094 (777.8 to 1539.2) | 853 (630.0 to 1154.3) | 877 (634.1 to 1212.7) | 1031 (745.8 to 1426.2) | 1092 (838.9 to 1421.3) |
| 19F (n = 37, 46, 41, 42, 63) | 346 (219.7 to 545.4) | 221 (146.8 to 331.9) | 165 (106.8 to 253.4) | 294 (191.8 to 450.2) | 279 (196.8 to 395.0) |
| 23F (n = 38, 45, 42, 42, 63) | 342 (211.6 to 552.6) | 441 (283.7 to 685.4) | 332 (210.0 to 523.4) | 321 (203.3 to 506.7) | 366 (252.4 to 532.1) |
| 1 (n = 42, 42, 43, 44, 74) | 12 (8.7 to 17.7) | 11 (7.5 to 15.4) | 8 (5.5 to 11.2) | 8 (5.4 to 10.9) | 12 (9.0 to 15.5) |
| 3 (n = 41, 41, 39, 39, 69) | 72 (57.4 to 91.1) | 76 (60.4 to 95.7) | 56 (44.1 to 70.8) | 62 (49.3 to 79.1) | 87 (73.1 to 104.3) |
| 5 (n = 42, 43, 44, 42, 73) | 86 (59.7 to 122.7) | 96 (67.4 to 137.3) | 54 (37.7 to 76.2) | 99 (69.1 to 142.0) | 76 (57.5 to 99.2) |
| 6A (n = 46, 42, 39, 39, 76) | 1060 (784.5 to 1431.1) | 1681 (1227.3 to 2302.3) | 1228 (886.0 to 1701.9) | 1281 (924.0 to 1775.1) | 1462 (1157.1 to 1847.1) |
| 7F (n = 46, 42, 40, 39, 76) | 1766 (1387.0 to 2247.7) | 1907 (1481.0 to 2454.6) | 1747 (1348.6 to 2263.3) | 1584 (1218.8 to 2058.9) | 2125 (1761.6 to 2564.6) |
| 19A (n = 42, 44, 41, 42, 74) | 185 (127.8 to 268.3) | 257 (178.5 to 368.5) | 163 (112.3 to 237.9) | 159 (110.0 to 230.9) | 240 (181.9 to 318.0) |
Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
| mcg/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series | 0.54 (0.44 to 0.66) | 0.59 (0.49 to 0.73) | 0.49 (0.40 to 0.60) | 0.51 (0.42 to 0.63) | 0.58 (0.49 to 0.69) |
Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.
| EU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Pertussis PT | 40.86 (36.49 to 45.76) | 43.51 (39.02 to 48.51) | 40.27 (36.09 to 44.93) | 39.26 (35.04 to 43.98) | 44.85 (40.84 to 49.25) |
| Pertussis FHA | 46.29 (41.49 to 51.65) | 40.65 (36.59 to 45.16) | 41.32 (37.16 to 45.94) | 35.55 (31.85 to 39.68) | 48.42 (44.22 to 53.01) |
| Pertussis PRN | 72.90 (63.26 to 84.01) | 71.26 (62.18 to 81.66) | 65.82 (57.38 to 75.50) | 68.53 (59.44 to 79.02) | 84.57 (75.21 to 95.09) |
Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
| IU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Tetanus | 0.73 (0.65 to 0.83) | 0.70 (0.62 to 0.79) | 0.69 (0.61 to 0.77) | 0.60 (0.53 to 0.68) | 0.82 (0.74 to 0.90) |
| Diphtheria | 0.62 (0.56 to 0.69) | 0.68 (0.61 to 0.75) | 0.61 (0.55 to 0.68) | 0.65 (0.59 to 0.73) | 0.65 (0.60 to 0.72) |
Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
| mIU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series | 756.42 (589.71 to 970.26) | 770.93 (608.34 to 976.98) | 689.34 (546.12 to 870.11) | 599.12 (470.78 to 762.43) | 733.29 (597.81 to 899.46) |
Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
| titer | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Poliomyelitis Type 1 | 68.11 (53.14 to 87.30) | 66.59 (52.98 to 83.68) | 67.43 (52.89 to 85.96) | 70.66 (54.73 to 91.23) | 72.02 (58.88 to 88.10) |
| Poliomyelitis Type 2 | 79.60 (61.54 to 102.95) | 73.52 (58.01 to 93.16) | 62.12 (48.30 to 79.90) | 55.17 (42.33 to 71.89) | 67.37 (54.67 to 83.02) |
| Poliomyelitis Type 3 | 246.22 (192.84 to 314.38) | 184.03 (146.96 to 230.46) | 257.92 (203.08 to 327.56) | 218.85 (170.18 to 281.44) | 231.02 (189.44 to 281.72) |
Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
| mcg/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose | 9.65 (7.74 to 12.03) | 9.35 (7.55 to 11.57) | 8.25 (6.69 to 10.16) | 7.84 (6.35 to 9.68) | 8.96 (7.53 to 10.67) |
Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\] and pertactin \[PRN\]) antibodies.
| EU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Pertussis PT | 77.43 (68.12 to 88.02) | 76.93 (68.13 to 86.87) | 73.72 (65.40 to 83.10) | 73.38 (64.96 to 82.90) | 74.01 (66.91 to 81.86) |
| Pertussis FHA | 115.55 (104.32 to 128.00) | 117.87 (106.98 to 129.87) | 123.56 (112.30 to 135.95) | 108.11 (98.09 to 119.16) | 117.01 (107.97 to 126.81) |
| Pertussis PRN | 158.28 (136.30 to 183.81) | 156.98 (136.24 to 180.87) | 160.96 (139.98 to 185.08) | 158.71 (137.67 to 182.97) | 172.80 (153.64 to 194.36) |
Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
| IU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Tetanus | 2.54 (2.28 to 2.83) | 2.50 (2.26 to 2.77) | 2.60 (2.35 to 2.88) | 2.29 (2.07 to 2.54) | 2.66 (2.44 to 2.89) |
| Diphtheria | 1.64 (1.49 to 1.80) | 1.94 (1.77 to 2.12) | 1.69 (1.54 to 1.84) | 1.87 (1.71 to 2.04) | 1.90 (1.77 to 2.05) |
Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
| mIU/mL | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose | 4868.61 (3750.57 to 6319.94) | 4148.04 (3234.82 to 5319.08) | 4250.41 (3320.88 to 5440.13) | 4263.28 (3330.93 to 5456.60) | 3866.37 (3146.78 to 4750.52) |
Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
| titer | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Poliomyelitis Type 1 | 399.56 (332.13 to 480.68) | 426.63 (357.15 to 509.62) | 443.97 (373.58 to 527.63) | 415.45 (348.48 to 495.29) | 406.37 (351.67 to 469.59) |
| Poliomyelitis Type 2 | 613.18 (515.30 to 729.65) | 586.30 (496.01 to 693.03) | 587.56 (499.47 to 691.18) | 605.78 (513.44 to 714.73) | 621.07 (542.07 to 711.57) |
| Poliomyelitis Type 3 | 1205.80 (1001.18 to 1452.24) | 1045.57 (874.35 to 1250.32) | 1210.29 (1017.32 to 1439.87) | 1187.11 (994.68 to 1416.76) | 1237.86 (1070.27 to 1431.70) |
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.6 EU/mL, FHA \>=16.1 EU/mL, PRN \>=24.0 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Hib PRP >=0.15 mcg/mL (n= 136, 146, 144, 139, 198) | 87.5 (80.7 to 92.5) | 84.2 (77.3 to 89.7) | 86.1 (79.4 to 91.3) | 85.6 (78.7 to 91.0) | 87.9 (82.5 to 92.1) |
| Hib PRP >=1 mcg/mL (n = 136, 146, 144, 139, 198) | 33.8 (25.9 to 42.4) | 37.0 (29.2 to 45.4) | 27.1 (20.0 to 35.1) | 28.1 (20.8 to 36.3) | 33.8 (27.3 to 40.9) |
| Pertussis PT >=14.6 EU/mL (n= 132,143,141,131,193) | 93.2 (87.5 to 96.8) | 97.2 (93.0 to 99.2) | 91.5 (85.6 to 95.5) | 90.8 (84.5 to 95.2) | 95.3 (91.3 to 97.8) |
| Pertussis FHA >=16.1 EU/mL (n=132,143,141,131,193) | 96.2 (91.4 to 98.8) | 92.3 (86.7 to 96.1) | 93.6 (88.2 to 97.0) | 88.5 (81.8 to 93.4) | 95.3 (91.3 to 97.8) |
| Pertussis PRN >=24.0 EU/mL (n=132,143,141,131,193) | 90.9 (84.7 to 95.2) | 87.4 (80.8 to 92.4) | 88.7 (82.2 to 93.4) | 89.3 (82.7 to 94.0) | 95.3 (91.3 to 97.8) |
| Tetanus >=0.1 IU/mL (n = 132,143,141,131,193) | 100.0 (97.2 to 100.00) | 100.0 (97.5 to 100.00) | 100.0 (97.4 to 100.00) | 98.5 (94.6 to 99.8) | 99.5 (97.1 to 100.0) |
| Diphtheria >=0.1 IU/mL (n = 132,143,141,131,193) | 100.0 (97.2 to 100.00) | 98.6 (95.0 to 99.8) | 99.3 (96.1 to 100.0) | 97.7 (93.5 to 99.5) | 99.5 (97.1 to 100.0) |
| HBV >= 10mIU/mL (n = 105,116,120,112,156) | 100.0 (96.5 to 100.0) | 99.1 (95.3 to 100.0) | 99.2 (95.4 to 100.0) | 99.1 (95.1 to 100.0) | 98.7 (95.4 to 99.8) |
| PoliomyelitisType1 >=1:8titer (n=89,105,93,84,135) | 97.8 (92.1 to 99.7) | 98.1 (93.3 to 99.8) | 97.8 (92.4 to 99.7) | 100.0 (95.7 to 100.0) | 99.3 (95.9 to 100.0) |
| PoliomyelitisType2 >=1:8titer (n=89,105,93,84,135) | 95.5 (88.9 to 98.8) | 98.1 (93.3 to 99.8) | 95.7 (89.4 to 98.8) | 96.4 (89.9 to 99.3) | 95.6 (90.6 to 98.4) |
| PoliomyelitisType3 >=1:8titer (n=89,105,93,84,135) | 100.0 (95.9 to 100.0) | 100.0 (96.5 to 100.0) | 98.9 (94.2 to 100.0) | 98.8 (93.5 to 100.0) | 99.3 (95.9 to 100.0) |
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate \[PRP\] \>=0.15 mcg/mL; Hib PRP \>=1 mcg/mL; Pertussis PT \>=14.8 EU/mL, FHA \>=46.5 EU/mL, PRN \>=43.5 EU/mL; Tetanus \>=0.1 IU/mL; Diphtheria \>=0.1 IU/mL; HBV \>=10 mIU/mL; Poliomyelitis Type 1, 2, 3 \>=1:8 titer) along with the corresponding 95% CIs were presented. Exact 2-sided CI based on the observed proportion of participants. Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Hib PRP >=0.15 mcg/mL (n= 126, 135, 141, 138, 202) | 100.0 (97.1 to 100.0) | 99.3 (95.9 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (98.2 to 100.0) |
| Hib PRP >=1 mcg/mL (n = 126, 135, 141, 138, 202) | 95.2 (89.9 to 98.2) | 96.3 (91.6 to 98.8) | 95.7 (91.0 to 98.4) | 95.7 (90.8 to 98.4) | 95.0 (91.1 to 97.6) |
| Pertussis PT >=14.8 EU/mL (n= 123,137,141,136,199) | 97.6 (93.0 to 99.5) | 99.3 (96.0 to 100.0) | 98.6 (95.0 to 99.8) | 100.0 (97.3 to 100.0) | 95.5 (91.6 to 97.9) |
| Pertussis FHA >=46.5 EU/mL (n=123,137,141,136,199) | 91.1 (84.6 to 95.5) | 94.9 (89.8 to 97.9) | 93.6 (88.2 to 97.0) | 92.6 (86.9 to 96.4) | 95.5 (91.6 to 97.9) |
| Pertussis PRN >=43.5 EU/mL (n=123,137,141,136,199) | 91.9 (85.6 to 96.0) | 94.9 (89.8 to 97.9) | 94.3 (89.1 to 97.5) | 94.1 (88.7 to 97.4) | 95.5 (91.6 to 97.9) |
| Tetanus >=0.1 IU/mL (n = 123,137,141,136,199) | 100.0 (97.0 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (98.2 to 100.0) |
| Diphtheria >=0.1 IU/mL (n = 123,137,141,136,199) | 100.0 (97.0 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (98.2 to 100.0) |
| HBV >= 10 mIU/mL (n = 119,131,133,133,191) | 100.0 (96.9 to 100.0) | 98.5 (94.6 to 99.8) | 100.0 (97.3 to 100.0) | 100.0 (97.3 to 100.0) | 99.5 (97.1 to 100.0) |
| Poliomyelitis 1 >=1:8titer (n=123,133,141,136,201) | 99.2 (95.6 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.3 to 100.0) | 99.5 (97.3 to 100.0) |
| Poliomyelitis 2 >=1:8titer (n=123,133,141,136,201) | 100.0 (97.0 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (98.2 to 100.0) |
| Poliomyelitis 3 >=1:8titer (n=123,133,141,136,201) | 100.0 (97.0 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (97.4 to 100.0) | 100.0 (97.3 to 100.0) | 100.0 (98.2 to 100.0) |
Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree Celsius (degree C), greater than (\>) 39 but \<=40 degree C and \>40 degree C.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Fever >=38, <=39 degree C (n= 149,157,147,155,187) | 32.9 | 45.2 | 18.4 | 34.2 | 41.7 |
| Fever >39, <=40 degree C (n = 138,145,137,146,170) | 1.4 | 1.4 | 0.7 | 0.7 | 1.2 |
| Fever >40 degree C (n = 138,145,137,146,170) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Fever >=38, <=39 degree C (n= 141,152,140,159,181) | 26.2 | 42.8 | 21.4 | 44.0 | 39.8 |
| Fever >39, <=40 degree C (n = 133,140,134,145,164) | 1.5 | 0.7 | 1.5 | 1.4 | 3.7 |
| Fever >40 degree C (n = 131,140,133,144,164) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C. Report of fever \>40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Fever >=38, <=39 degree C (n= 136,146,135,141,175) | 22.1 | 30.8 | 17.0 | 33.3 | 29.7 |
| Fever >39, <=40 degree C (n = 129,137,125,136,167) | 1.6 | 2.9 | 0.8 | 1.5 | 1.8 |
| Fever >40 degree C (n = 128,136,126,135,166) | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 |
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary. Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics. Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected. The highest temperature for each day was recorded in the e-diary. Incidences of fever were presented in following categories: \>=38 but \<=39 degree C, \>39 but \<=40 degree C and \>40 degree C.
| percentage of participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Fever >=38, <=39 degree C (n= 133,140,134,144,162) | 31.6 | 37.1 | 37.3 | 50.0 | 30.2 |
| Fever >39, <=40 degree C (n = 128,127,118,123,150) | 5.5 | 7.1 | 4.2 | 5.7 | 2.0 |
| Fever >40 degree C (n = 123,125,117,122,150) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
| participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Non-SAEs | 57 | 71 | 67 | 72 | 80 |
| SAEs | 7 | 3 | 11 | 8 | 10 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment).
| participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Non-SAEs | 3 | 6 | 3 | 4 | 8 |
| SAEs | 6 | 14 | 10 | 11 | 9 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state. Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
| participants | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa |
|---|---|---|---|---|---|
| Non-SAEs | 47 | 57 | 52 | 76 | 50 |
| SAEs | 3 | 2 | 1 | 1 | 1 |
Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study. Participants recorded pre-specified AEs in electronic diary: fever (up to 4 days after each vaccine dose).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series | — | 7/173 (4%) | 57/173 (32.9%) |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series | — | 3/176 (1.7%) | 71/176 (40.3%) |
| 13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series | — | 11/172 (6.4%) | 67/172 (39%) |
| 13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series | — | 8/177 (4.5%) | 72/177 (40.7%) |
| 13vPnC + INFANRIX Hexa - Infant Series | — | 10/210 (4.8%) | 80/210 (38.1%) |
| 13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser | — | 6/170 (3.5%) | 3/170 (1.8%) |
| 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser | — | 14/174 (8%) | 6/174 (3.4%) |
| 13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser | — | 10/172 (5.8%) | 3/172 (1.7%) |
| 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser | — | 11/176 (6.3%) | 4/176 (2.3%) |
| 13vPnC + INFANRIX Hexa - After Infant Series | — | 9/210 (4.3%) | 8/210 (3.8%) |
| 13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose | — | 3/169 (1.8%) | 47/169 (27.8%) |
| 13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose | — | 2/173 (1.2%) | 57/173 (32.9%) |
| 13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose | — | 1/170 (0.6%) | 52/170 (30.6%) |
| 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose | — | 1/175 (0.6%) | 76/175 (43.4%) |
| 13vPnC + INFANRIX Hexa - Toddler Dose | — | 1/209 (0.5%) | 50/209 (23.9%) |
| Event | 13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series | 13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series | 13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series | 13vPnC + INFANRIX Hexa - Infant Series | 13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser | 13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser | 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser | 13vPnC + INFANRIX Hexa - After Infant Series | 13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose | 13vPnC + INFANRIX Hexa - Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/173 | 0/176 | 0/172 | 1/177 | 1/210 | 2/170 | 4/174 | 0/172 | 1/176 | 0/210 | 0/169 | 0/173 | 1/170 | 0/175 | 0/209 |
| PneumoniaInfections and infestations | 2/173 | 0/176 | 3/172 | 2/177 | 2/210 | 1/170 | 1/174 | 2/172 | 2/176 | 1/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Gastroenteritis rotavirusInfections and infestations | 0/173 | 0/176 | 0/172 | 0/177 | 0/210 | 0/170 | 3/174 | 1/172 | 0/176 | 0/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| DiarrhoeaGastrointestinal disorders | 0/173 | 1/176 | 0/172 | 0/177 | 1/210 | 0/170 | 1/174 | 1/172 | 2/176 | 3/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Head injuryInjury, poisoning and procedural complications | 0/173 | 0/176 | 0/172 | 0/177 | 1/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 2/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| BronchopneumoniaInfections and infestations | 2/173 | 0/176 | 0/172 | 0/177 | 1/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Upper respiratory tract infectionInfections and infestations | 0/173 | 0/176 | 1/172 | 0/177 | 0/210 | 0/170 | 2/174 | 0/172 | 1/176 | 0/210 | 0/169 | 1/173 | 0/170 | 0/175 | 0/209 |
| BronchitisInfections and infestations | 0/173 | 0/176 | 1/172 | 2/177 | 0/210 | 0/170 | 1/174 | 0/172 | 2/176 | 0/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Urinary tract infectionInfections and infestations | 1/173 | 2/176 | 1/172 | 2/177 | 0/210 | 0/170 | 0/174 | 1/172 | 2/176 | 0/210 | 0/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Viral infectionInfections and infestations | 0/173 | 0/176 | 0/172 | 0/177 | 0/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 1/169 | 0/173 | 0/170 | 0/175 | 0/209 |
| Event | 13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series | 13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series | 13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series | 13vPnC + INFANRIX Hexa - Infant Series | 13vPnC +INFANRIX Hexa +Paracetamol Twice Daily -After Inf Ser | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser | 13vPnC+INFANRIX Hexa +Paracetamol Thrice Daily -After Inf Ser | 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -After Inf Ser | 13vPnC + INFANRIX Hexa - After Infant Series | 13vPnC +INFANRIX Hexa + Paracetamol Twice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa + Ibuprofen Twice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose | 13vPnC +INFANRIX Hexa +Ibuprofen Thrice Daily -Toddler Dose | 13vPnC + INFANRIX Hexa - Toddler Dose |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever >=38, <=39 degree CGeneral disorders | 49/149 | 71/157 | 27/147 | 53/155 | 78/187 | — | — | — | — | — | 42/133 | 52/140 | 50/134 | 72/144 | 49/162 |
| Fever >=38, <=39 degree CGeneral disorders | 37/141 | 65/152 | 30/140 | 70/159 | 72/181 | — | — | — | — | — | — | — | — | — | — |
| Fever >=38, <=39 degree CGeneral disorders | 30/136 | 45/146 | 23/135 | 47/141 | 52/175 | — | — | — | — | — | — | — | — | — | — |
| Upper respiratory tract infectionInfections and infestations | 15/173 | 12/176 | 14/172 | 17/177 | 12/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 7/169 | 7/173 | 3/170 | 4/175 | 7/209 |
| NasopharyngitisInfections and infestations | 11/173 | 6/176 | 10/172 | 8/177 | 18/210 | 0/170 | 0/174 | 0/172 | 0/176 | 1/210 | 1/169 | 2/173 | 4/170 | 2/175 | 1/209 |
| Fever >39, <=40 degree CGeneral disorders | 2/138 | 2/145 | 1/137 | 1/146 | 2/170 | — | — | — | — | — | 7/128 | 9/127 | 5/118 | 7/123 | 3/150 |
| BronchitisInfections and infestations | 9/173 | 8/176 | 11/172 | 9/177 | 5/210 | 0/170 | 0/174 | 0/172 | 0/176 | 1/210 | 2/169 | 0/173 | 3/170 | 5/175 | 2/209 |
| RhinitisInfections and infestations | 3/173 | 7/176 | 11/172 | 10/177 | 9/210 | 0/170 | 0/174 | 1/172 | 0/176 | 0/210 | 2/169 | 4/173 | 5/170 | 3/175 | 5/209 |
| ConjunctivitisEye disorders | 1/173 | 3/176 | 7/172 | 5/177 | 0/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 1/169 | 0/173 | 0/170 | 0/175 | 1/209 |
| Respiratory tract infectionInfections and infestations | 4/173 | 7/176 | 4/172 | 5/177 | 3/210 | 0/170 | 0/174 | 0/172 | 0/176 | 0/210 | 0/169 | 1/173 | 0/170 | 6/175 | 2/209 |
| Age, Continuous(days) | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa | Total |
|---|---|---|---|---|---|---|
| Mean | 65.1 ± 9.5 | 66.5 ± 10.1 | 65.6 ± 9.7 | 66.4 ± 10.3 | 65.6 ± 9.4 | 65.8 ± 9.8 |
| Sex: Female, Male(Participants) | 13vPnC + INFANRIX Hexa + Paracetamol Twice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily | 13vPnC + INFANRIX Hexa + Paracetamol Thrice Daily | 13vPnC + INFANRIX Hexa + Ibuprofen Thrice Daily | 13vPnC + INFANRIX Hexa | Total |
|---|---|---|---|---|---|---|
| Female | 87 | 89 | 75 | 79 | 98 | 428 |
| Male | 86 | 87 | 97 | 98 | 112 | 480 |
The record gives a start of Aug 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine